A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC)
- Conditions
- Advanced Gastrointestinal Tumors
- Interventions
- Biological: LCAR-G08 cells
- Registration Number
- NCT06197178
- Lead Sponsor
- Peking University
- Brief Summary
This is a phase 1, single-arm, open-label, dose escalation and expansion study of LCAR-G08 in adult subjects with advanced gastrointestinal tumors expressing guanylyl cyclase C (GCC).
- Detailed Description
This is a phase 1, single-arm, open-label, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profiles of the cell-based LCAR- G08 in subjects with guanylyl cyclase C (GCC)-positive advanced gastrointestinal tumors. Subjects who meet the eligibility criteria will receive LCAR-G08 infusion. The study will include the following sequential phases: screening, pre-treatment (cell product preparation; lymphodepleting chemotherapy), treatment and follow up.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 42
- Voluntary agreement to provide written informed consent.
- Histologically confirmed metastatic colorectal cancers and other advanced gastrointestinal cancers (esophageal cancer, gastric cancer, pancreatic cancer, and small bowel cancer).
- Aged 18 to 70 years, either sex.
- GCC immunohistochemistry (IHC) staining is positive.
- At least one measurable tumor lesion according to RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Expected survival ≥ 3 months.
- Clinical laboratory values meet screening visit criteria.
- Previous CAR-T cell, T cell receptor-engineered (TCR) T cell, or therapeutic tumor vaccination treatment within the past 6 months; and the corresponding CAR-T, TCR-T cells can still be detected.
- Ever received any treatment targeting GCC.
- Prior antitumor therapy with insufficient washout period.
- Brain metastases.
- Pregnant or lactating women.
- Hepatitis C virus (HCV) antibody-positive or human immunodeficiency virus (HIV) antibody-positive, active syphilis, Epstein-Barr virus (EBV) infected.
- Severe underlying disease.
- Presence of other serious pre-existing medical conditions that may limit patient participation in the study.Any condition that, in the investigator's judgment, will make the subject unsuitable for participation in this study.
Any condition that, in the investigator's judgment, will make the subject unsuitable for participation in this study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Chimeric Antigen Receptor T cell LCAR-G08 Cells LCAR-G08 cells Each subject will receive LCAR-G08 Cells
- Primary Outcome Measures
Name Time Method Maximum concentration (Cmax) Minimum 2 years after LCAR-G08 infusion (Day 1) The maximum observed concentration of CAR positive T cells or transgene CAR copy number after LCAR-G08 infusion.
Time to Cmax (Tmax) Minimum 2 years after LCAR-G08 infusion (Day 1) The time it takes to reach the maximum concentration or time to Cmax after LCAR-G08 infusion.
Recommended Phase 2 Dose (RP2D) regimen finding Minimum 2 years after LCAR-G08 infusion (Day 1) RP2D established through accelerated titration design (ATD) and Bayesian Optimal Interval (BOIN) design.
Dose-limiting toxicity (DLT) rate Minimum 2 years after LCAR-G08 infusion (Day 1) Dose-limiting toxicity (DLT) refers to a drug-related toxicity during treatment with the drug, the severity of which is clinically unacceptable, limiting the further escalation of drug dose.
Time to the last observed concentration Minimum 2 years after LCAR-G08 infusion (Day 1) The time it takes to reach the last observed concentration after LCAR-G08 infusion.
Area Under the Curve (AUC) last Minimum 2 years after LCAR-G08 infusion (Day 1) The total exposure of the drug experienced by the subject in a clinical study from LCAR-G08 infusion to time to the last observed concentration.
Incidence, severity, and type of treatment-emergent adverse events (TEAEs) Minimum 2 years after LCAR-G08 infusion (Day 1) An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment.
- Secondary Outcome Measures
Name Time Method Progression-free Survival (PFS) after administration Minimum 2 years after LCAR-G08 infusion (Day 1) Progression-free Survival (PFS) is defined as the time from the date of first infusion of the LCAR-G08 to the first documented disease progression (according to RECIST 1.1) or death (due to any cause), whichever occurs first.
Time to Response (TTR) after administration Minimum 2 years after LCAR-G08 infusion (Day 1) Time to Response (TTR) is defined as the time from the date of first infusion of LCAR-G08 to the date of the first response evaluation of the subject who has met all criteria for PR or better.
Incidence of anti-LCAR-G08 antibody and positive sample titer Minimum 2 years after LCAR-G08 infusion (Day 1) Venous blood samples will be collected to measure LCAR-G08 positive cell concentrations and the transgenic level of LCAR-G08, at the time points when anti-LCAR-G08 antibody serum samples are evaluated.
Disease Control Rate (DCR) after administration Minimum 2 years after LCAR-G08 infusion (Day 1) Disease Control Rate (DCR) is defined as the proportion of patients with complete response, partial response and stable disease.
Objective Response Rate (ORR) after administration Minimum 2 years after LCAR-G08 infusion (Day 1) Objective Response Rate (ORR) is defined as the proportion of subjects who achieve complete response (CR) or partial response (PR) after treatment via LCAR-G08 cell infusion, and the objective tumor response rate will be calculated for patients with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 only.
Duration of Remission (DoR) after administration Minimum 2 years after LCAR-G08 infusion (Day 1) Duration of Remission (DoR) is defined as the time from the first documentation of remission (PR or better) to the first documented disease progression evidence (according to RECIST 1.1) of the responders (who achieve PR or better response).se).
Overall Survival (OS) after administration Minimum 2 years after LCAR-G08 infusion (Day 1) Overall Survival (OS) is defined as the time from the date of first infusion of LCAR-G08 to death of the subject.
Trial Locations
- Locations (2)
Beijing GoBroad Hospital
🇨🇳Beijing, Beijing, China
Beijing Cancer Hospital & Institute
🇨🇳Beijing, Beijing, China